Table 3: Graft survival relative to posttransplantation variables.

No. of
patients
5-year
survival %
95% CI10-year
survival %
95% CIP value
(log rank)

Induction therapy
 No110886.584.3488.6664.661.6667.540.536
 Yes 85987.184.7589.4569.564.8074.20
Primary immunosuppression
 (i) Aza-based (dual therapy) 30982.277.6986.7158.352.4264.18<0.001
 (ii) CsA-based (dual therapy) 30384.879.1290.4857.849.7665.84
 (iii) CsA-based (triple therapy) 98886.984.7489.0666.563.3669.64
 (iv) Tacrolimus-based (triple therapy) 21791.688.2794.9386.280.9191.49
 (v) Sirolimus-based therapy 8588.982.0495.76
Total steroid dose
(during first 3 months)
 <5 gm115889.387.3491.2670.366.7773.83<0.001
 5–10 gm 60185.082.0687.9464.860.6868.92
 >10 gm 20877.972.0283.7846.939.6554.15
No. of acute rejection episodes
(during first 3 months)
 (i) No 70894.292.4495.9682.178.1886.02<0.001
 (ii) One 66189.687.2591.9569.465.2873.52
 (iii) ≥2 59875.872.2779.3347.543.1951.81
Urological complications
 (i) No181687.085.4388.5765.963.3568.450.449
 (ii) Yes 15183.677.5289.6861.451.9970.81
Post-transplant hypertension
 (i) Normotensive75886.283.4688.9475.771.5879.82<0.001
 (ii) Sustained hypertension80988.085.6590.4565.962.1869.62
 (iii) Newly developed hypertension40085.782.1789.2356.050.7161.29